Farmacología

2013

1. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach

   Pediatric Drugs, Vol. 15, Núm. 3, pp. 247-257

2. A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior

   Neuropsychopharmacology, Vol. 38, Núm. 9, pp. 1724-1736

3. Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain

   European Journal of Pharmacology, Vol. 709, Núm. 1-3, pp. 13-19

4. An investigation of interactions between hypocretin/orexin signaling and glutamate receptor surface expression in the rat nucleus accumbens under basal conditions and after cocaine exposure

   Neuroscience Letters, Vol. 557, Núm. PB, pp. 101-106

5. Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms

   Journal of Psychiatric Research, Vol. 47, Núm. 7, pp. 926-934

6. Antidepressant-like properties of three new α2-adrenoceptor antagonists

   Neuropharmacology, Vol. 65, pp. 13-19

7. Antipsychotics and seizures: Higher risk with atypicals?

   Seizure, Vol. 22, Núm. 2, pp. 141-143

8. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.

   Translational psychiatry, Vol. 3

9. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment

   Psychopharmacology, Vol. 226, Núm. 1, pp. 177-188

10. Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment

    European Neuropsychopharmacology, Vol. 23, Núm. 3, pp. 229-239

11. Chronic pain leads to concomitant noradrenergic impairment and mood disorders

    Biological Psychiatry, Vol. 73, Núm. 1, pp. 54-62

12. Cooperativity between calmodulin-binding sites in Kv7.2 channels

    Journal of Cell Science, Vol. 126, Núm. 1, pp. 244-253

13. Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: Basal contents and effects of psychotropic medications

    International Journal of Neuropsychopharmacology, Vol. 16, Núm. 3, pp. 683-689

14. Description of a bivalent cannabinoid ligand with hypophagic properties

    Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179

15. Determination of total plasma hydroperoxides using a diphenyl-1- pyrenylphosphine fluorescent probe

    Analytical Biochemistry, Vol. 434, Núm. 1, pp. 172-177

16. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?

    Current drug safety, Vol. 8, Núm. 1, pp. 63-68

17. Dopamine-dependent long-term depression at subthalamo-nigral synapses is lost in experimental parkinsonism

    Journal of Neuroscience, Vol. 33, Núm. 36, pp. 14331-14341

18. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects

    European Neuropsychopharmacology, Vol. 23, Núm. 8, pp. 852-864

19. Eosinophilia associated with bupropion

    International Journal of Clinical Pharmacy, Vol. 35, Núm. 4, pp. 532-534

20. Ethanol reversal of cellular tolerance to morphine in rat locus coeruleus neurons

    Molecular Pharmacology, Vol. 84, Núm. 2, pp. 252-260